%0 Journal Article
%T Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
%A Aditya Bardia
%A Beth Overmoyer
%A Carlos R. Gil Del Alcazar
%A Daniel G. Stover
%A Eric P. Winer
%A Franziska Michor
%A Hao Guo
%A Jane Brock
%A Justin Balko
%A Kornelia Polyak
%A Maxwell Lloyd
%A Nancy U. Lin
%A Qiong Xu
%A Rebecca Gelman
%A Sara M. Tolaney
%A Vivian Wang
%A Yaomin Xu
%A Yu Wang
%J Archive of "NPJ Breast Cancer".
%D 2018
%R 10.1038/s41523-018-0060-z
%X CONSORT diagra
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935675/